Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02876900 · ClinicalTrials.gov registry record · Phase 3
Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.
A Phase 3 study, sponsored by Noven Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 617
- Enrollment target
NCT02876900: Completed Phase 3 study, sponsored by Noven Pharmaceuticals.
NCT02876900 is a Phase 3 study that has completed, run by Noven Pharmaceuticals. The registered enrollment target is 617 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02876900, a Phase 3 study, has completed, sponsored by Noven Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 617 participants
- Enrollment target
Study Summary
This study is designed to evaluate efficacy and safety of HP-3070 compared with placebo transdermal patch in subjects diagnosed with schizophrenia.
Interventions
- DRUG Placebo
- DRUG Low Dose Asenapine maleate transdermal patch
- DRUG High Dose Asenapine maleate transdermal patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 617 participants |
| Start Date | 2016-08 |
| Est. Completion | 2018-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02876900
The ClinicalTrials.gov registry entry for NCT02876900 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 617 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% lower). The listed sponsor is Noven Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02876900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02876900 about?
NCT02876900 is a clinical study titled "Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.". This study is designed to evaluate efficacy and safety of HP-3070 compared with placebo transdermal patch in subjects diagnosed with schizophrenia.
What is the current status of trial NCT02876900?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 617 participants. The study started on 2016-08. Estimated completion is 2018-06.
What interventions are being tested in trial NCT02876900?
The interventions under investigation include: Placebo (DRUG), Low Dose Asenapine maleate transdermal patch (DRUG), High Dose Asenapine maleate transdermal patch (DRUG).
Who is sponsoring clinical trial NCT02876900?
This trial is sponsored by Noven Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.